Equities analysts forecast that ICU Medical, Inc. (NASDAQ:ICUI) will post sales of $321.44 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ICU Medical’s earnings. The lowest sales estimate is $313.40 million and the highest is $329.48 million. ICU Medical posted sales of $96.72 million during the same quarter last year, which suggests a positive year-over-year growth rate of 232.3%. The company is expected to announce its next quarterly earnings report after the market closes on Wednesday, August 9th.

According to Zacks, analysts expect that ICU Medical will report full year sales of $321.44 million for the current fiscal year, with estimates ranging from $1.23 billion to $1.25 billion. For the next fiscal year, analysts expect that the firm will post sales of $1.33 billion per share, with estimates ranging from $1.32 billion to $1.34 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for ICU Medical.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, May 10th. The medical instruments supplier reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $1.23. ICU Medical had a net margin of 18.76% and a return on equity of 9.63%. The business had revenue of $247.74 million for the quarter, compared to the consensus estimate of $237.12 million. During the same period in the previous year, the firm earned $1.26 EPS. The business’s revenue for the quarter was up 175.7% on a year-over-year basis.

ICUI has been the topic of several recent research reports. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $195.00 target price on the stock in a research note on Wednesday, July 12th. Roth Capital lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call. Sidoti lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 20th. Finally, BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. ICU Medical currently has an average rating of “Hold” and a consensus target price of $156.00.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/321-44-million-in-sales-expected-for-icu-medical-inc-icui-this-quarter.html.

In related news, VP Alison D. Burcar sold 18,290 shares of the stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $160.72, for a total value of $2,939,568.80. Following the sale, the vice president now directly owns 3,727 shares in the company, valued at approximately $599,003.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Vivek Jain sold 100,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $170.80, for a total transaction of $17,080,000.00. Following the completion of the sale, the chairman now owns 110,925 shares in the company, valued at $18,945,990. The disclosure for this sale can be found here. Insiders sold a total of 227,349 shares of company stock worth $38,623,370 over the last quarter. 15.90% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of ICU Medical by 87,088.7% in the first quarter. BlackRock Inc. now owns 1,769,930 shares of the medical instruments supplier’s stock worth $270,268,000 after buying an additional 1,767,900 shares in the last quarter. Janus Capital Management LLC increased its stake in shares of ICU Medical by 178.8% in the first quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock worth $219,864,000 after buying an additional 923,395 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of ICU Medical by 12.1% in the first quarter. Wellington Management Group LLP now owns 652,897 shares of the medical instruments supplier’s stock worth $99,697,000 after buying an additional 70,283 shares in the last quarter. Champlain Investment Partners LLC increased its stake in shares of ICU Medical by 4.6% in the first quarter. Champlain Investment Partners LLC now owns 496,220 shares of the medical instruments supplier’s stock worth $75,773,000 after buying an additional 21,630 shares in the last quarter. Finally, GW&K Investment Management LLC increased its stake in shares of ICU Medical by 2.7% in the second quarter. GW&K Investment Management LLC now owns 495,697 shares of the medical instruments supplier’s stock worth $85,508,000 after buying an additional 12,808 shares in the last quarter. Institutional investors and hedge funds own 77.85% of the company’s stock.

ICU Medical (NASDAQ:ICUI) traded down 0.35% during mid-day trading on Friday, hitting $170.95. 26,675 shares of the company were exchanged. ICU Medical has a 12-month low of $116.22 and a 12-month high of $176.50. The company has a 50 day moving average of $172.15 and a 200 day moving average of $157.46. The stock has a market cap of $3.38 billion, a P/E ratio of 30.39 and a beta of 0.37.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.